Pipeline
We are developing therapies to counteract the devastating progression of neurodegenerative diseases.
Target & Modality
Candidate
Phase 3
Alector’s Commercial Ownership
Rights
ABC = Alector Brain Carrier
FTD-GRN = Frontotemporal Dementia with a GRN gene mutation
AD = Alzheimer’s Disease
PD = Parkinson’s Disease
GD = Gaucher Disease
LBD = Lewy Body Dementia
Aβ = Amyloid Beta
Abs = Antibodies
ERT = Enzyme Replacement Therapy
SiRNA = Small Interference Ribonucleic Acid (RNA)
UD = Undisclosed
Close
Latozinemab
Target
PGRN-Abs
Indication
FTD- GRN
Development Stage
Phase 3
AL001 modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. We are initially developing AL001 for frontotemporal dementia (FTD) with progranulin mutation (FTD-GRN). The global INFRONT-3 Phase 3 clinical trial is currently enrolling both at-risk and symptomatic participants with FTD-GRN.
Close
AL101
Target
PGRN
Indication
AD
Development Stage
Phase 2
AL101 is designed to increase progranulin levels for the treatment of more prevalent neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. Mutations that moderately reduce the expression levels of PGRN have been shown to increase the risk of developing Alzheimer’s disease and Parkinson’s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in animal models.
AL101 is currently being studied in a Phase 2 clinical trial designed to assess its safety and efficacy in slowing disease progression in individuals with early Alzheimer’s disease. AL101 is being developed in collaboration with GSK.
Close
ADP037-ABC
Target
Aβ-Abs
Indication
AD
Development Stage
Preclinical
ADP037-ABC is a proprietary anti-amyloid beta (Aβ) antibody paired with the company’s ABC for the treatment of AD. It is designed to remove brain amyloid plaques, with the potential to reduce the risk of amyloid-related imaging abnormalities (ARIA) and enable subcutaneous delivery. It targets a validated epitope specific to brain amyloid plaques, combined with an optimized antibody constant region to enhance phagocytosis of Aβ plaques. By leveraging ABC technology, ADP037-ABC aims to clear Aβ efficiently, thereby reducing plaque accumulation and slowing disease progression while minimizing ARIA.
Close
ADP050-ABC
Target
GCase-ERT
Indication
PD, GD, LBD
Development Stage
Preclinical
ADP050-ABC is a GCase replacement therapy paired with the company’s proprietary ABC for GBA gene mutation carriers with Parkinson’s disease and Lewy body dementia. In these patients, mutations in the GBA gene lead to deficient GCase activity. ADP050-ABC uses Alector-engineered GCase, which has been designed to have a longer half-life and to break down glucocerebroside, a lipid that accumulates in neurons and contributes to neurodegeneration. This mechanism aims to reduce cellular dysfunction and slow disease progression.
Close
ADP056
Target
Reelin-UD
Indication
AD
Development Stage
ADP056 is a reelin modulator designed to block tau pathology and promote synaptic function in AD. Reelin, a large, secreted protein, regulates neuronal function and tau accumulation. Gain-of-function reelin variants protect against familial AD through a mechanism that appears to uncouple amyloid and tau pathology. ADP056 is designed to mimic and exceed these protective effects of the reelin mutation.
Close
ADP063-ABC
Target
Tau-Abs
Indication
AD
Development Stage
ADP063-ABC targets tau pathology in Alzheimer’s disease. It combines a proprietary anti-tau antibody with Alector Brain Carrier and an optimized antibody constant region. It is designed to block the spread of tau aggregates and has the potential for subcutaneous delivery, with the aim of potentially slowing cognitive decline.
Close
ADP064-ABC
Target
Tau-siRNA
Indication
AD, FTD
Development Stage
ADP064-ABC targets tau pathology in Alzheimer’s disease. It combines an anti tau siRNA, which aims to prevent the synthesis of the tau mRNA and protein, with Alector Brain Carrier, to potentially slow cognitive decline.